𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases

✍ Scribed by T.K. Sasikumar; Li Qiang; Duane A. Burnett; William J. Greenlee; Brian E. Hawes; Timothy J. Kowalski; Kim O’Neill; Brian D. Spar; Blair Weig

Book ID
108074111
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
132 KB
Volume
16
Category
Article
ISSN
0960-894X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synthesis and SAR of 4-aryl-1-(indazol-5
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity
✍ Mark Hadden; Dustin M. Deering; Alan J. Henderson; Matthew D. Surman; Michele Lu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 645 KB

A new series of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones possessing MCH-1 receptor antagonism is presented. Suzuki coupling of boronic acids with key triflate 6 allowed rapid generation of a range of analogs. The SAR of the MCH-1 receptor was explored with a variety of aryl and heterocyclic moieties

Novel imidazobenzazepine derivatives as
Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders
✍ Massimo Gianotti; Corrado Corti; Sonia Delle Fratte; Romano Di Fabio; Colin P. L 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 515 KB

A novel imidazobenzazepine template (5a) with potent dual H(1)/5-HT(2A) antagonist activity was identified. Application of a zwitterionic approach to this poorly selective and poorly developable starting point successfully delivered a class of high quality leads, 3-[4-(3-R(1)-2-R-5H-imidazo[1,2-b][2

Development of CDD-0102 as a selective M
Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease
✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope

Central type Ca2+ channel modulators as
Central type Ca2+ channel modulators as targets for the novel treatment of psychiatric diseases
✍ Yasuo Watanabe 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

In order to develop novel central acting drugs, the modulation of intracellular Ca 2 dynamics must be considered as an essential factor, since following excessive Ca 2 in¯ux to neuronal cells, abnormal intracellular Ca 2 concentrations induce several types of mental and neurological disorders. This